Genetic Risk Assessments in Individuals at High Risk for Inherited Breast Cancer in the Breast Oncology Care Setting

Claus E.B. , Schildkraut J.M. , Thompson W.D. . The genetic attributable risk of breast and ovarian cancer. Cancer. 1996; 77(11): 2318–2324.

Risch H.A. , McLaughlin J.R. , Cole D.E. . Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68(3): 700–710.

Narod S.A. , Offit K. . Prevention and management of hereditary breast cancer. J Clin Oncol. 2005; 23(8): 1656–1663.

Malone K.E. , Daling J.R. , Doody D.R. . Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006; 66(16): 8297–8308.

Pal T. , Permuth-Wey J. , Betts J.A. . BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104(12): 2807–2816.

Rubin S.C. , Blackwood M.A. , Bandera C. . BRCA1, BRCA2 and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998; 178(4): 670–677.

Antoniou A. , Pharoah P.D. , Narod S. . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72(5): 1117–1130.

Litton J.K. , Ready K. , Chen H. . Earlier age of onset of BRCA mutationrelated cancers in subsequent generations. Cancer. 2012; 118(2): 321–325.

Chen S. , Parmigiani G. . Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25(11): 1329–1333.

King M.C. , Marks J.H. , Mandell J.B. . Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302(5645): 643–646.

Moller P. , Maehle L. , Vabo A. , Clark N. , Sun P. , Narod S. . Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. Clin Genet. Feb 9.

Graeser M.K. , Engel C. , Rhiem K. . Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009; 27(35): 5887–5892.

Malone K.E. , Begg C.B. , Haile R.W. . Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010; 28(14): 2404–2410.

Watson M. , Kash K.M. , Homewood J. . Does genetic counseling have any impact on management of breast cancer risk? Genet Test. 2005; 9(2): 167–174.

Roukos D.H. , Briasoulis E. . Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007; 4(10): 578–590.

Weitzel J.N. , Blazer K.R. , Macdonald D.J. . Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin. 2011 Aug 19. Epub ahead of print.

Audeh M.W. , Penson R.T. , Friedlander M. . Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol. 2009; 27: 15s (suppl; abstr 5500).

Fong P.C. , Boss D.S. , Yap T.A. . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2): 123–134.

Tutt A. , Robson M. , Garber J.E. . Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol. 2009; 27(15 suppl): CRA501. Abstract

Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Practice Guidelines. V.1.2012. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed June 21, 2012.

Parmigiani G. , Berry D. , Aguilar O. . Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998; 62(1): 145–158.

Myriad Genetics, Laboratories and Pharmaceuticals. http://www.myriadtests.com/provider/brca-mutation-prevalence.htm. Accessed June 21, 2012.

Euhus D.M. , Smith K.C. , Robinson L. . Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002; 94(11): 844–851.

Kang H.H. , Williams R. , Leary J. . Evaluation of models to predict BRCA germline mutations. Br J Cancer. 2006; 95(7): 914–920.

Antoniou A.C. , Hardy R. , Walker L. . Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008; 45(7): 425–431.

Tai Y.C. , Chen S. , Parmigiani G. . Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res. 2008; 10(2): 401.

Biswas S. , Tankhiwale N. , Blackford A. . Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2012; 133(1): 347–355.

Mavaddat N. , Rebbeck T.R. , Lakhani S.R. . Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res. 2010; 12(3): R28.

Rubinstein W.S. . Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer. 2008; 7(1): 83–89.

Gronwald J. , Tung N. , Foulkes W.D. . Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006; 118(9): 2281–2284.

Narod S.A. , Brunet J.S. , Ghadirian P. . Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000; 356(9245): 1876–1881.

Pierce L.J. , Levin A.M. , Rebbeck T.R. . Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006; 24(16): 2437–2443.

Hartmann L.C. , Sellers T.A. , Schaid D.J. . Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001; 93(21): 1633–1637.

Rebbeck T.R. , Friebel T. , Lynch H.T. . Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22(6): 1055–1062.

Meijers-Heijboer H. , van Geel B. , van Putten W.L. . Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345(3): 159–164.

van Sprundel T.C. , Schmidt M.K. , Rookus M.A. . Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005; 93(3): 287–292.

Evans D.G. , Baildam A.D. , Anderson E. . Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet. 2009; 46(4): 254–258.

Heemskerk-Gerritsen B.A. , Brekelmans C.T. , Menke-Pluymers M.B. . Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007; 14(12): 3335–3344.

Domchek S.M. , Friebel T.M. , Singer C.F. . Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304(9): 967–975.

Finch A. , Beiner M. , Lubinski J. . Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006; 296(2): 185–192.

Rebbeck T.R. , Kauff N.D. , Domchek S.M. . Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009; 101(2): 80–87.

Eisen A. , Lubinski J. , Klijn J. . Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005; 23(30): 7491–7496.

Kauff N.D. , Domchek S.M. , Friebel T.M. . Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008; 26(8): 1331–1337.

Narod S.A. . BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol. 2010; 7(12): 702–707.

Metcalfe K. , Gershman S. , Lynch H.T. . Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011; 104(9): 1384–1392.

Kurian A.W. , Sigal B.M. , Plevritis S.K. . Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010; 28(2): 222–231.

Kurian A.W. , Munoz D.F. , Rust P. . Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol. 2012; 30(5): 497–506.

Bevers T.B. , Anderson B.O. , Bonaccio E. . NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009; 7(10): 1060–1096.

Murphy C.G. , Moynahan M.E. . BRCA gene structure and function in tumor suppression: a repair-centric perspective. Cancer J. 2010; 16(1): 39–47.

Narod S.A. , Lubinski J. , Ghadirian P. . Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol. 2006; 7(5): 402–406.

Andrieu N. , Easton D.F. , Chang-Claude J. . Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol. 2006; 24(21): 3361–3366.

Goldfrank D. , Chuai S. , Bernstein J.L. . Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev. 2006; 15(11): 2311–2313.

Warner E. , Plewes D.B. , Hill K.A. . Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004; 292(11): 1317–1325.

Leach M.O. , Boggis C.R. , Dixon A.K. . Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005; 365(9473): 1769–1778.

Kuhl C. , Weigel S. , Schrading S. . Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010; 28(9): 1450–1457.

Rijnsburger A.J. , Obdeijn I.M. , Kaas R. . BRCAl-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow- up of the Dutch MRISC Screening Study. J Clin Oncol. 2010; 28(36): 5265–5273.

Weinstein S.P. , Localio A.R. , Conant E.F. . Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol. 2009; 27(36): 6124–6128.

Sardanelli F. , Podo F. , Santoro F. . Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol. 2011; 46(2): 94–105.

Warner E. , Hill K. , Causer P. . Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011; 29(13): 1664–1669.

Obdeijn I.M. , Loo C.E. , Rijnsburger A.J. . Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition. Breast Cancer Res Treat. 2010; 119(2): 399–407.

Shah P. , Rosen M. , Stopfer J. . Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat. 2009; 118(3): 539–546.

Gulati A.P. , Domchek S.M. . The clinical management of BRCA1 and BRCA2 mutation carriers. Curr Oncol Rep. 2008; 10(1): 47–53.

Nusbaum R. , Isaacs C. . Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther. 2007; 11(3): 133–144.

Smith K.L. , Isaacs C. . Management of women at increased risk for hereditary breast cancer. Breast Dis. 2006; 27: 51–67.

Trainer A.H. , Lewis C.R. , Tucker K. . The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol. 2010; 7(12): 708–717.

Metcalfe K.A. , Birenbaum-Carmeli D. , Lubinski J. . International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008; 122(9): 2017–2022.

Schwartz M.D. , Lerman C. , Brogan B. . Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004; 22(10): 1823–1829.

Weitzel J.N. , McCaffrey S.M. , Nedelcu R. . Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. 2003; 138(12): 1323–1328; discussion 1329.

Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996; 14(5): 1730–1736; discussion 1737-1740.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003; 21(12): 2397–2406.

Robson M.E. , Storm C.D. , Weitzel J. . American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010; 28(5): 893–901.

The American Society of Breast Surgeons. BRCA Genetic Testing for Patients With and Without Breast Cancer. 2006. http://www.breastsurgeons.org/statements/brca.php. Accessed June 27, 2012.

Levy D.E. , Byfield S.D. , Comstock C.B. . Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genet Med. 2011; 13(4): 349–255.

Pierce L.J. , Phillips K.A. , Griffith K.A. . Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010; 121(2): 389–398.

Kirova Y.M. , Savignoni A. , Sigal-Zafrani B. . Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Longterm results and review of the literature. Breast Cancer Res Treat. 2010; 120(1): 119–126.

Metcalfe K. , Lynch H.T. , Ghadirian P. . Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2011; 127(1): 287–296.

Tung N. . Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA. 2011; 305(21): 2211–2220.

Mansfield C. . Effects of radiation therapy on wound healing after mastectomy. Clin Plast Surg. 1979; 6(1): 19–26.

Vandeweyer E. , Deraemaecker R. . Radiation therapy after immediate breast reconstruction with implants. Plast Reconstr Surg. 2000; 106(1): 56–58; discussion 59-60.

Daly M.B. . Tailoring breast cancer treatment to genetic status: the challenges ahead. J Clin Oncol. 2004; 22(10): 1776–1777.

Fedier A. , Steiner R.A. , Schwarz V.A. . The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003; 22(5): 1169–1173.

Chabalier C. , Lamare C. , Racca C. . BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006; 5(9): 1001–1007.

Byrski T. , Gronwald J. , Huzarski T. . Response to neoadjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008; 108(2): 289–296.

Wysocki P.J. , Korski K. , Lamperska K. . Primary resistance to docetaxelbased chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit. 2008; 14(7): SC7–SC10.

Bhattacharyya A. , Ear U.S. , Koller B.H. . The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2000; 275(31): 23899–23903.

Gronwald J. , Byrski T. , Huzarski T. . Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol. 2009; 27(15s suppl): 502. Abstract.

Silver D.P. , Richardson A.L. , Eklund A.C. . Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010; 28(7): 1145–1153.

Bolderson E. , Richard D.J. , Zhou B.B. . Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res. 2009; 15(20): 6314–6320.

McCabe N. , Turner N.C. , Lord C.J. . Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16): 8109–8115.

Tutt A.N. , Lord C.J. , McCabe N. . Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol. 2005; 70: 139–148.

Plummer E.R. . Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol. 2006; 6(4): 364–368.

James C.R. , Quinn J.E. , Mullan P.B. . BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist. 2007; 12(2): 142–150.

Tuma R.S. . Combining carefully selected drug, patient genetics may lead to total tumor death. J Natl Cancer Inst. 2007; 99(20): 1505–1506, 1509.

Jones C. , Plummer E.R. . PARP inhibitors and cancer therapy: early results and potential applications. Br J Radiol. 2008; 81 Spec No 1: S2-5.

Ashworth A. . A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double- strand break repair. J Clin Oncol. 2008; 26(22): 3785–3790.

Tutt A. , Robson M. , Garber J.E. . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737): 235–244.

Metcalfe K.A. , Lynch H.T. , Ghadirian P. . The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005; 96(1): 222–226.

Frost M.H. , Schaid D.J. , Sellers T.A. . Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 2000; 284(3): 319–324.

Metcalfe K.A. , Semple J.L. , Narod S.A. . Satisfaction with breast reconstruction in women with bilateral prophylactic mastectomy: a descriptive study. Plast Reconstr Surg. 2004; 114(2): 360–366.

Stefanek M.E. , Helzlsouer K.J. , Wilcox P.M. . Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med. 1995; 24(4): 412–419.

Frost M.H. , Slezak J.M. , Tran N.V. . Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005; 23(31): 7849–7856.

Geiger A.M. , West C.N. , Nekhlyudov L. . Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006; 24(9): 1350–1356.

Bresser P.J. , Seynaeve C. , Van Gool A.R. . Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg. 2006; 117(6): 1675–1682; discussion 1683-1674.

Madalinska J.B. , Hollenstein J. , Bleiker E. . Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005; 23(28): 6890–6898.

Chen C.L. , Weiss N.S. , Newcomb P. . Hormone replacement therapy in relation to breast cancer. JAMA. 2002; 287(6): 734–741.

Rossouw J.E. , Anderson G.L. , Prentice R.L. . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321–333.

Chlebowski R.T. , Hendrix S.L. , Langer R.D. . Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003; 289(24): 3243–3253.

Eisen A. , Lubinski J. , Gronwald J. . Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008; 100(19): 1361–1367.

Rebbeck T.R. , Friebel T. , Wagner T. . Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005; 23(31): 7804–7810.

Anderson G.L. , Chlebowski R.T. , Aragaki A.K. . Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012; 13(5): 476–486.

Madalinska J.B. , Essink-Bot M.L. , de Koning H.J. . Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate. 2001; 46(2): 87–97.

Partridge A.H. , Gelber S. , Peppercorn J. . Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004; 22(20): 4174–4183.

Lee S. , Schover L. , Partridge A. . American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006; 24: 2917–2931.

The Ethics Committee of the American Society for Reproductive. Medicine fertility preservation and reproduction in cancer patients. Fertil Steril. 2005; 83(6): 1622–1628.

Schover L.R. , Rybicki L.A. , Martin B.A. . Having children after cancer. Cancer. 1999; 86(4): 697–709.

Partridge A.H. , Gelber S. , Peppercorn J. . Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004 2004; 22(20): 4174–4183.

Quinn G.P. , Vadaparampil S.T. , Lee J.H. . Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009; 27(35): 5952–5957.

Staton A.D. , Kurian A.W. , Cobb K. . Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer. 2008; 7(2): 179–186.

Friedman L.C. , Kramer R.M. . Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr. 2005; (34): 83–86.

Smith K.R. , Ellington L. , Chan A.Y. . Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev. 2004; 13(5): 733–740.

Quinn G. , Vadaparampil S. , Wilson C. . Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril. 2009; 91(6): 2361–2368.

Ogilvie C.M. , Braude P.R. , Scriven P.N. . Preimplantation genetic diagnosis: an overview. J Histochem Cytochem. 2005; 53(3): 255–260.

Baruch S. , Kaufman D. , Hudson K.L. . Genetic testing of embryos: practices and perspectives of US in vitro fertilization clinics. Fertil Steril. 2008; 89(5): 1053–1058.

Dayal M.B. , Athanasiadis I. . Preimplantation Genetic Diagnosis. http://www.emedicine.com/med/topic3520.htm#section~bibliography. Accessed June 28, 2012.

Offit K. , Kohut K. , Clagett B. . Cancer genetic testing and assisted reproduction. J Clin Oncol. 2006; 24(29): 4775–4782.

Kim S.S. , Klemp J. , Fabian C. . Breast cancer and fertility preservation. Fertil Steril. 2011; 95(5): 1535–1543.

Jacobsen P.B. , Valdimarsdottier H.B. , Brown K.L. . Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med. 1997; 59(5): 459–466.

Sussner K.M. , Jandorf L. , Thompson H.S. . Interest and beliefs about BRCA genetic counseling among at-risk Latinas in New York City. J Genet Couns. 2010; 19(3): 255–268.

Vadaparampil S.T. , Quinn G.P. , Dutil J. . A pilot study of knowledge and interest of genetic counseling and testing for hereditary breast and ovarian cancer syndrome among Puerto Rican women. J Community Genet. 2011; 2(4): 211–221.

Vadaparampil S.T. , Quinn G.P. , Small B.J. . A pilot study of hereditary breast and ovarian knowledge among a multiethnic group of Hispanic women with a personal or family history of cancer. Genet Test Mol Biomarkers. 2010; 14(1): 99–106.

Offit K. , Groeger E. , Turner S. . The “duty to warn” a patient's family members about hereditary disease risks. JAMA. 2004; 292(12): 1469–1473.

Finlay E. , Stopfer J.E. , Burlingame E. . Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test. 2008; 12(1): 81–91.

Kenen R. , Arden-Jones A. , Eeles R. . Healthy women from suspected hereditary breast and ovarian cancer families: the significant others in their lives. Eur J Cancer Care (Engl). 2004; 13(2): 169–179.

MacDonald D.J. , Sarna L. , van Servellen G. . Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet Med. 2007; 9(5): 275–282.

Patenaude A.F. , Dorval M. , DiGianni L.S. . Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol. 2006; 24(4): 700–706.

Wagner Costalas J. , Itzen M. , Malick J. . Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet C Semin Med Genet. 2003; 119C(1): 11–18.

Dancyger C. , Wiseman M. , Jacobs C. , etc. Communicating BRCA1/2 genetic test results within the family: a qualitative analysis. Psychol Health. 2011; 26(8): 1018–1035.

Loud J.T. , Weissman N.E. , Peters J.A. . Deliberate deceit of family members: a challenge to providers of clinical genetics services. J Clin Oncol. 2006; 24(10): 1643–1646.

Bradbury A.R. , Dignam J.J. , Ibe C.N. . How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007; 25(24): 3705–3711.

Bradbury A.R. , Patrick-Miller L. , Pawlowski K. . Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology. 2009; 18(2): 200–208.

Sharff M.E. , Demarco T.A. , Mays D. . Parenting through genetic uncertainty: themes in the disclosure of breast cancer risk information to children. Genet Test Mol Biomarkers. 2012; 16(5): 376–382.

Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet. 1995; 57(5): 1233–1241.

Robson M.E. , Storm C.D. , Weitzel J. . American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010; 28(5): 893–901.

Committee on Bioethics. Ethical issues with genetic testing in pediatrics. Pediatrics. 2001; 107(6): 1451–1455.

Wertz D.C. , Fanos J.H. , Reilly P.R. . Genetic testing for children and adolescents. Who decides? JAMA. 1994; 272(11): 875–881.

Leib J.R. , Hoodfar E. , Haidle J.L. . The new genetic privacy law. Commun Oncol. 2008; 5(6): 124–127.

Baruch S. , Hudson K. . Civilian and military genetics: nondiscrimination policy in a post-GINA world. Am J Hum Genet. 2008; 83(4): 435–444.

American Cancer Society. Cancer Facts & Figures 2011. http://www.cancer.org/Research/CancerFactsFigures/index. Accessed June 28, 2012.

Vos J. , Jansen A.M. , Menko F. . Family communication matters: the impact of telling relatives about unclassified variants and uninformative DNA-test results. Genet Med. 2011; 13(4): 333–341.

Vos J. , Menko F. , Jansen A.M. , van Asperen C.J. . A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer. 2011; 10(1): 87–96.

Vos J. , Oosterwijk J.C. , Gomez-Garcia E. . Perceiving cancer-risks and heredity-likelihood in genetic-counseling: how counselees recall and interpret BRCA 1/2-test results. Clin Genet. 2011; 79(3): 207–218.

Berliner J.L. , Fay AM Practice Issues Subcommittee of the National Society of Genetic Counselors’ Familial Cancer Risk Counseling Special Interest Group. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007; 16(3): 241–260.

Cancer-Related Genetic Testing and Counseling: Workshop Proceedings. National Cancer Policy Forum; Institute of Medicine. National Academy of Sciences, Washington, DC; 2007. http://www.nap.edu/catalog/11971.html. Accessed June 28, 2012.

Riley B.D. , Culver J.O. , Skrzynia C. . Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012; 21(2): 151–161.

American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins: Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009; 113(4): 957–966.

Oncology Nursing Society. The Role of the Oncology Nurse in Cancer Genetic Counseling. [2009; http://www.ons.org/Publications/Positions/Genetic-Counseling/. Accessed June 28, 2012.

Radford C. . Understanding the Evolution of and Term “Genetic Counselor”: Is the Term Being Used Appropriately in Your Community? Oncol Nurse. 2011; 4(5): 24–25. http://www.theoncologynurse.com/article/understanding-evo-lution-and-term-%E2%80%9Cgenetic-counselor%E2%80%9D-term-being-used-appropriately-your-comm.

Geier L.J. , Mulvey T.M. , Weitzel J.N. . Clinical cancer genetics remains a specialized area: how do I get there from here? 2009 Educational Book. American Society of Clinical Oncology. http://www.asco.org/ASCOv2/Home/Education%20&%20Training/Educational%20Book/PDF%20Files/2009/09EdBk.PractMgmt.03.pdf. Accessed June 29, 2012.

Cohen S.A. , McIlvried D. , Schnieders J. . A collaborative approach to genetic testing: a community hospital's experience. J Genet Couns. 2009; 18(6): 530–533.

DeMarco T.A. , Smith K.L. , Nusbaum R.H. . Practical aspects of delivering hereditary cancer risk counseling. Semin Oncol. 2007; 34(5): 369–378.

MacDonald D.J. , Blazer K.R. , Weitzel J.N. . Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Canc Netw. 2010; 8(5): 615–624.

Esserman L. , Kaklamani V. . Lessons learned from genetic testing. JAMA. 2010; 304(9): 1011–1012.

Brierley K.L. , Campfield D. , Ducaine W. . Errors in delivery of cancer genetics services: implications for practice. Conn Med. 2010; 74(7): 413–423.

Lawrence W.F. , Peshkin B.N. , Liang W. . Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev. 2001; 10(5): 475–481.

Schwartz G.F. , Hughes K.S. , Lynch H.T. . Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer. 2008; 113(10): 2627–2637.

Hampel H. , Sweet K. , Westman J.A. . Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet. 2004; 41(2): 81–91.

Weitzel J.N. . Genetic cancer risk assessment. Putting it all together. Cancer. 1999; 86(11 suppl): 2483–2492.

Ganz P.A. , Kwan L. , Somerfield M.R. . The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol. 2006; 24(18): 2948–2957.

McPherson E. , Zaleski C. , Benishek K. . Clinical genetics provider realtime workflow study. Genet Med. 2008; 10(9): 699–706.

Bernhardt B.A. , Tumpson J.E. , Pyeritz R.E. . The economics of clinical genetics services. IV. Financial impact of outpatient genetic services on an academic institution. Am J Hum Genet. 1992; 50(1): 84–91.

Vadaparampil S.T. , Quinn G.P. , Miree C.A. . Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients. Ann Surg Oncol. 2009; 16(7): 1973–1981.

Vadaparampil S.T. , Quinn G.P. , Brzosowicz J. . Experiences of genetic counseling for BRCA1/2 among recently diagnosed breast cancer patients: a qualitative inquiry. J Psychosoc Oncol. 2008; 26(4): 33–52.

Vadaparampil S.T. , Quinn G.P. , Lee J.H. . Satisfaction with physician recommendation for and information about genetic counseling among breast cancer patients. Breast J. 2011; 17(1): 79–82.

Acheson L.S. , Stange K.C. , Zyzanski S. . Clinical genetics issues encountered by family physicians. Genet Med. 2005; 7(7): 501–508.

Vig H.S. , Armstrong J. , Egleston B.L. . Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers. 2009; 13(6): 735–741.

(ASCO) ASoCO. Cancer Genetics and Cancer Predisposition Testing. 2nd ed. Alexandria, VA: American Society of Clinical Oncology Publishing; 2004.

National Cancer Policy Forum, Institute of Medicine. Cancer-Related Genetic Testing and Counseling: Workshop Proceedings. The National Academies Press; 2007.

Daly M.B. , Axilbund J.E. , Buys S. . Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010; 8(5): 562–594.

Calzone K.A. , Jenkins J. , Masny A. . Core competencies in cancer genetics for advanced practice oncology nurses. Oncol Nurs Forum. 2002; 29(9): 1327–1333.

Genetic testing in adoption. The American Society of Human Genetics Social Issues Committee and The American College of Medical Genetics Social, Ethical, and Legal Issues Committee. Am J Hum Genet. 2000; 66(3): 761–767.

Kolb S.E. , Aguilar M.C. , Dinenberg M. , Kaye C.I. . Genetics education for primary care providers in community health settings. J Community Health. 1999; 24(1): 45–59.

Korf B.R. . Medical education in the ‘postgenomic era’. Postgrad Med. 2000; 108(3): 15–18.

Peterson S.K. , Rieger P.T. , Marani S.K. . Oncology nurses’ knowledge, practice, and educational needs regarding cancer genetics. Am J Med Genet. 2001; 98(1): 3–12.

Reynolds P.P. , Benkendorf J.L. . Genes and generalists: why we need professionals with added competencies. West J Med. 1999; 171(5-6): 375–379.

Schwartz M.D. , Valdimarsdottir H.B. , DeMarco T.A. . Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol. 2009; 28(1): 11–19.

Ozanne E.M. , Loberg A. , Hughes S. . Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J. 2009; 15(2): 155–162.

Drohan B. , Ozanne E.M. , Hughes K.S. . Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J. 2009; 15 suppl 1: S46–S55.

Drohan B. , Roche C.A. , Cusack J.C. Jr . Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers. Ann Surg Oncol. 2012; 19(6): 1732–1737.

Zon R.T. , Goss E. , Vogel V.G. . American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol. 2009; 27(6): 986–993.